Beam Therapeutics Inc.(BEAM)今日盘中股价大涨14%,引发市场关注。公司所处的基因编辑行业被看好,成为股价上涨的主要推手。
公开信息显示,知名机构投资者ARK Invest基金经理Cathie Wood看好Beam Therapeutics等基因编辑公司的长期发展前景。她表示,无论谁当选总统,科技行业监管将减少,有利于变革性技术的兴起,基因编辑便是其中之一。作为该领域的先驱企业,Beam Therapeutics有望凭借自身技术优势受益于行业发展红利。
此外,市场对Beam Therapeutics业绩增长保持乐观预期。公司最新财报显示,营收同比增长,毛利率也有所提高。不过,分析师也对公司后续发展存在不同观点,有所调降目标价格。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.